Thromb Haemost 2019; 119(12): 1920-1926
DOI: 10.1055/s-0039-1696687
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study

Massimo Radin*
1   Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy
,
Karen Schreiber*
2   Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom
3   Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark
,
Savino Sciascia
1   Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy
,
Dario Roccatello
1   Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy
,
Irene Cecchi
1   Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy
,
María Ángeles Aguirre Zamorano
4   Department of Rheumatology, University Hospital “Reina Sofia,” Cordoba, Spain
,
Maria Jose Cuadrado
5   Department of Rheumatology, Clinica Universidad de Navarra, Madrid, Spain
› Author Affiliations
Funding None.
Further Information

Publication History

03 May 2019

19 July 2019

Publication Date:
06 October 2019 (online)

Abstract

Objective This article aims to analyse the rate of antiphospholipid antibodies (aPL) negativisation in patients with antiphospholipid syndrome (APS), and to evaluate potential new clinical manifestations after negativisation and/or aPL fluctuations in a long-term follow-up.

Methods Inclusion criteria are (1) any patients with an APS diagnosis according to the current Sydney criteria and (2) patients in whom aPL negativisation occurred. aPL negativisation was defined as repeated aPL measurements on at least two consecutive occasions at least 12 weeks apart, with a follow-up of at least 1 year since aPL first turned negative.

Results Out of 259 APS patients, a total of 23 patients (8.9%) met the inclusion criteria for persistent aPL negativisation. Patients were followed-up for 14.4 ± 8.1 years, experienced aPL negativisation after a mean of 5.3 ± 3.5 years and were followed-up after experiencing the aPL negativisation for a mean of 7.6 ± 5.8 years. Seventeen patients (73.9%) presented with thrombotic APS, 2 with pregnancy morbidity (8.7%) and 4 (17.4%) with both. Most of the patients (18; 78.3%) had a single aPL positivity, 5 (21.7%) double, while no triple aPL positivity was observed. At the time of data collection, after aPL negativisation, anticoagulation was stopped in 8 patients with previous thrombotic venous event (8/21, 38%) according to the treating physicians' judgements. None of the patients experienced any recurrent thrombotic event during the follow-up period after their aPL negativisation.

Conclusion In our patient cohort consisting of 259 patients with definitive APS, we observed over a mean observation period of > 5 years, that aPL negativisation occurred in approximately 9% of patients. Negativisation occurred most often in patients who were previously found to be positive for only one aPL.

Authors' Contributions

M.R., S.S., I.C. and K.S. retrieved data from patients' files, drafted the manuscript and tables and critically reviewed the manuscript. M.R., S.S., I.C., D.R., M.A. and M.C. drafted the manuscript and critically reviewed the manuscript.


* Equally contributed to this study.


 
  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
  • 2 Radin M, Cecchi I, Pérez-Sánchez C. Antiphospholipid antibodies negativization: time for testing for non-criteria aPL?. Lupus 2017; 26 (13) 1457-1458
  • 3 Sciascia S, Coloma-Bazán E, Radin M. , et al. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?. Autoimmun Rev 2017; 16 (11) 1109-1114
  • 4 Filippidou N, Krashias G, Pericleous C. , et al. The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. Mol Immunol 2016; 75: 161-167
  • 5 Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost 2008; 34 (03) 282-285
  • 6 Erkan D, Derksen WJM, Kaplan V. , et al. Real world experience with antiphospholipid antibody tests: how stable are results over time?. Ann Rheum Dis 2005; 64 (09) 1321-1325
  • 7 Pengo V, Ruffatti A, Del Ross T. , et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013; 11 (08) 1527-1531
  • 8 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
  • 9 Devreese KMJ, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. ; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12 (05) 792-795
  • 10 Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect- and direct-acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a coagulation reference laboratory. Am J Clin Pathol 2017; 147 (06) 632-640
  • 11 Antovic A, Norberg E-M, Berndtsson M. , et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb Haemost 2017; 117 (09) 1700-1704
  • 12 Medina G, Briones-García E, Cruz-Domínguez MP, Flórez-Durante OI, Jara LJ. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: thrombosis recurrence. Autoimmun Rev 2017; 16 (04) 352-354
  • 13 Comarmond C, Jego P, Veyssier-Belot C. , et al. Cessation of oral anticoagulants in antiphospholipid syndrome. Lupus 2017; 26 (12) 1291-1296
  • 14 Bertolaccini ML, Amengual O, Andreoli L. , et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13 (09) 917-930
  • 15 Conti F, Priori R, Alessandri C. , et al. Diagnosis of catastrophic anti-phospholipid syndrome in a patient tested negative for conventional tests. Clin Exp Rheumatol 2017; 35 (04) 678-680
  • 16 Nuri E, Taraborelli M, Andreoli L. , et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017; 65 (01) 17-24
  • 17 Rand JH, Wu X-X, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112 (05) 1687-1695
  • 18 Sciascia S, Naretto C, Rossi D, Bazzan M, Roccatello D. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 2011; 20 (10) 1106-1108
  • 19 Sciascia S, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Ann Rheum Dis 2018; 77 (11) 1694-1695
  • 20 Mahdy AA, Raafat HA, El-Fishawy HS, Gheita TA. Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients. Bull Fac Pharmacy . Cairo Univ Elsevier 2014; 52: 37-43
  • 21 Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 2017; 16 (03) 411-419
  • 22 Sciascia S, Willis R, Pengo V. , et al; APS ACTION. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thromb Res 2019; 175: 32-36
  • 23 Tincani A, Filippini M, Scarsi M, Galli M, Meroni P. European attempts for the standardisation of the antiphospholipid antibodies. Lupus 2009; 18: 913-919
  • 24 Tektonidou MG, Andreoli L, Limper M. , et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019 pii: annrheumdis-2019–215213